Corcept Therapeutics downgraded to Underweight from Neutral at Piper Jaffray

theflyonthewall.com

Piper Jaffray downgraded Corcept Therapeutics to Underweight citing the positive FDA panel vote for Novartis’s Signifor, a direct competitor to Corcept's Korlym. The firm lowered its price target for shares to $1.10 from $3.

View Comments (0)